Europe Pharmacogenomics Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)

No. of Pages: 171
Report Code: TIPRE00028855
Category: Life Sciences
Europe Pharmacogenomics Market
Free Sample Buy Now

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. Europe Pharmacogenomics Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Europe Pharmacogenomics Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. Europe Pharmacogenomics Market Regional Analysis

6.2 Europe Pharmacogenomics Market Revenue 2019-2028 (US$ Million)
6.3 Europe Pharmacogenomics Market Forecast Analysis

7. Europe Pharmacogenomics Market Analysis – by Technology

7.1 PCR
  • 7.1.1 Overview
  • 7.1.2 PCR: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Sequencing
  • 7.2.1 Overview
  • 7.2.2 Sequencing: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Microarray
  • 7.3.1 Overview
  • 7.3.2 Microarray: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Gel Electrophoresis
  • 7.4.1 Overview
  • 7.4.2 Gel Electrophoresis: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.5 Mass Spectrometry
  • 7.5.1 Overview
  • 7.5.2 Mass Spectrometry: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)

8. Europe Pharmacogenomics Market Analysis – by Application

8.1 Drug Discovery
  • 8.1.1 Overview
  • 8.1.2 Drug Discovery: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Oncology
  • 8.2.1 Overview
  • 8.2.2 Oncology: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.3 Neurology and Psychiatry
  • 8.3.1 Overview
  • 8.3.2 Neurology and Psychiatry: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.4 Pain Management
  • 8.4.1 Overview
  • 8.4.2 Pain Management: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.5 Cardiovascular Diseases
  • 8.5.1 Overview
  • 8.5.2 Cardiovascular Diseases: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)

9. Europe Pharmacogenomics Market Analysis – by End User

9.1 Hospitals and Clinics
  • 9.1.1 Overview
  • 9.1.2 Hospitals and Clinics: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Biopharmaceutical Companies
  • 9.2.1 Overview
  • 9.2.2 Biopharmaceutical Companies: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 CROs and CDMOs
  • 9.3.1 Overview
  • 9.3.2 CROs and CDMOs: Europe Pharmacogenomics Market – Revenue and Forecast, 2019-2028 (US$ Million)

10. Europe Pharmacogenomics Market – Europe Analysis

10.1 Overview

10.2 Europe
  • 10.2.1 Europe Pharmacogenomics Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.2.1.1 Europe Pharmacogenomics Market – Revenue and Forecast Analysis – by Country
  • 10.2.1.1 UK: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.2.1.1.1 UK: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.2.1.1.2 UK: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.2.1.1.3 UK: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.2.1.2 Germany: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.2.1.2.1 Germany: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.2.1.2.2 Germany: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.2.1.2.3 Germany: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.2.1.3 France: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.2.1.3.1 France: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.2.1.3.2 France: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.2.1.3.3 France: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.2.1.4 Russia: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.2.1.4.1 Russia: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.2.1.4.2 Russia: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.2.1.4.3 Russia: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.2.1.5 Italy: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.2.1.5.1 Italy: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.2.1.5.2 Italy: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.2.1.5.3 Italy: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.2.1.6 Rest of Europe: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.2.1.6.1 Rest of Europe: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.2.1.6.2 Rest of Europe: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.2.1.6.3 Rest of Europe: Europe Pharmacogenomics Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments

13. Company Profiles

13.1 Abbott
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 F. HOFFMANN-LA ROCHE LTD.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Oxford Nanopore Technologies
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Illumina, Inc.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 QIAGEN
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Agilent Technologies, Inc.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Myriad Genetics, Inc.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights
14.2 List of Abbreviations

The List of Companies - Europe Pharmacogenomics Market

  • Abbott
  • F. HOFFMANN-LA ROCHE LTD.
  • Oxford Nanopore Technologies
  • THERMO FISHER SCIENTIFIC INC.
  • Illumina, Inc.
  • QIAGEN
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.

    • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)